Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 308

1.

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.

Hanif W, Malik W, Hassanein M, Kamal A, Geransar P, Andrews C, Azam M, Barnett AH.

Curr Med Res Opin. 2013 Jul;29(7):807-11. doi: 10.1185/03007995.2013.803054. Epub 2013 May 31.

PMID:
23659561
2.

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.

Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, Andrews C, Barnett A.

Curr Med Res Opin. 2011 Jul;27(7):1367-74. doi: 10.1185/03007995.2011.579951. Epub 2011 May 16.

PMID:
21568833
3.

The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.

Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, Hristoskova S, Ditommaso S, Kadwa MY.

Int J Clin Pract. 2013 Oct;67(10):957-63. doi: 10.1111/ijcp.12243. Epub 2013 Sep 3.

4.

Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.

Mahar SA, Hasan MI, Khan MI, Fawwad A, Hussain S, Maheshwary N, Kumar K, Siddiqi A, Khan MA.

J Pak Med Assoc. 2014 Nov;64(11):1297-302.

6.

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.

Göke R, Gruenberger JB, Bader G, Dworak M.

Curr Med Res Opin. 2014 May;30(5):785-9. doi: 10.1185/03007995.2013.875464. Epub 2014 Jan 17.

PMID:
24328429
8.

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.

Lukashevich V, Del Prato S, Araga M, Kothny W.

Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2.

9.

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Filozof C, Gautier JF.

Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x. Erratum in: Diabet Med. 2013 May;30(5):632.

PMID:
20536495
10.

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

Devendra D, Gohel B, Bravis V, Hui E, Salih S, Mehar S, Hassanein M.

Int J Clin Pract. 2009 Oct;63(10):1446-50. doi: 10.1111/j.1742-1241.2009.02171.x. Epub 2009 Aug 12.

PMID:
19678856
11.

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

Diabetes Obes Metab. 2008 Nov;10(11):1047-56. doi: 10.1111/j.1463-1326.2008.00859.x. Epub 2008 Feb 18.

PMID:
18284434
12.

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators.

Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.

PMID:
22369287
13.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x. Epub 2009 Apr 13.

PMID:
19515179
14.

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.

Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P.

Metabolism. 2014 Jul;63(7):957-67. doi: 10.1016/j.metabol.2014.04.008. Epub 2014 Apr 23.

PMID:
24874591
15.

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.

Yang W, Xing X, Lv X, Li Y, Ma J, Yuan G, Sun F, Wang W, Woloschak M, Lukashevich V, Kozlovski P, Kothny W; all investigators.

J Diabetes. 2015 Mar;7(2):174-81. doi: 10.1111/1753-0407.12169. Epub 2014 Jul 29.

PMID:
24823599
16.

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S.

Diabetes Metab. 2012 Oct;38(4):359-66. doi: 10.1016/j.diabet.2012.06.001. Epub 2012 Jul 17.

PMID:
22809630
17.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
18.

Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.

Xiaoyan C, Jing W, Xiaochun H, Yuyu T, Shunyou D, Yingyu F.

Curr Med Res Opin. 2016 Jun;32(6):1131-6. doi: 10.1185/03007995.2016.1162773. Epub 2016 Mar 23.

PMID:
26950829
19.

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.

Diabetes Care. 2007 Apr;30(4):890-5. Epub 2007 Feb 2.

PMID:
17277036
20.

Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.

Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.

J Med Econ. 2014 Jul;17(7):499-507. doi: 10.3111/13696998.2014.912986. Epub 2014 Apr 23.

PMID:
24708176

Supplemental Content

Support Center